This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Fabry disease is a lysosomal storage disease that involves severe kidney disease, cardiac disease, cerebrovascular disease, and early death for affected individuals. This study is a multicenter, multinational, open-label trial to confirm the safety and effectiveness of Fabrazyme in patients with advanced Fabry disease who received either Fabrazyme or placebo as treatment for Fabry disease in the AGAL-008-00 trial. The primary objective is to evaluate the stabilization of renal function with Fabrazyme.
Showing the most recent 10 out of 563 publications